GlassScriptPhysician profile
Teo Soleymani
NPI 1447679865
$17,926.98
in general payments reported to CMS, 2019-2025
16 companies · $17K in 2025
The $17K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.16 · 2023: $143 · 2024: $310 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $2,196 · Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,764.00 |
| Travel and Lodging | $2,196.10 |
| Food and Beverage | $1,935.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $16,307.72 | 2023-2025 | Libtayo |
| Organogenesis INC. | $370.41 | 2023-2025 | Cygnus Dual, Puraply, Affinity |
| Abbvie INC. | $359.24 | 2024-2025 | |
| Genzyme Corporation | $225.75 | 2024-2025 | |
| Ucb, INC. | $158.07 | 2025 | Bimzelx |
| Incyte Corporation | $94.23 | 2025 | Opzelura |
| Galderma Laboratories, L.P. | $83.50 | 2024-2025 | Nemluvio, Dysport |
| Kyowa Kirin, INC. | $58.86 | 2025 | |
| Leo Pharma INC. | $52.43 | 2025 | Adbry |
| Janssen Biotech, INC. | $46.36 | 2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $44.42 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $31.16 | 2020 | |
| Pfizer INC. | $29.96 | 2023 | |
| Lilly USA, LLC | $28.29 | 2025 | Ebglyss, Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $19.58 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $17.00 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teo Soleymani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.